EBS vs. MACK, RIGL, XOMA, VSTM, RGLS, VNDA, LXRX, OPK, QURE, and PBYI
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Verastem (VSTM), Regulus Therapeutics (RGLS), Vanda Pharmaceuticals (VNDA), Lexicon Pharmaceuticals (LXRX), OPKO Health (OPK), uniQure (QURE), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
Merrimack Pharmaceuticals (NASDAQ:MACK) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
Merrimack Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Merrimack Pharmaceuticals has higher earnings, but lower revenue than Emergent BioSolutions. Emergent BioSolutions is trading at a lower price-to-earnings ratio than Merrimack Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions received 12 more outperform votes than Merrimack Pharmaceuticals when rated by MarketBeat users. However, 66.89% of users gave Merrimack Pharmaceuticals an outperform vote while only 66.45% of users gave Emergent BioSolutions an outperform vote.
Emergent BioSolutions has a consensus target price of $5.00, indicating a potential downside of 9.91%. Given Merrimack Pharmaceuticals' higher possible upside, analysts clearly believe Emergent BioSolutions is more favorable than Merrimack Pharmaceuticals.
In the previous week, Merrimack Pharmaceuticals had 5 more articles in the media than Emergent BioSolutions. MarketBeat recorded 6 mentions for Merrimack Pharmaceuticals and 1 mentions for Emergent BioSolutions. Emergent BioSolutions' average media sentiment score of 0.92 beat Merrimack Pharmaceuticals' score of -0.03 indicating that Merrimack Pharmaceuticals is being referred to more favorably in the media.
Merrimack Pharmaceuticals has a net margin of 0.00% compared to Merrimack Pharmaceuticals' net margin of -47.68%. Emergent BioSolutions' return on equity of -1.93% beat Merrimack Pharmaceuticals' return on equity.
Summary
Merrimack Pharmaceuticals beats Emergent BioSolutions on 11 of the 16 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
